DSIP

What it is

DSIP (delta sleep-inducing peptide) is a nine–amino-acid peptide (a nonapeptide) with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu S1. It was first isolated in the mid-1970s from the cerebral venous blood of rabbits during induced sleep-like states, and named for the delta (slow-wave) EEG activity seen in those early experiments S1. Despite that name, decades of work have not identified a DSIP gene, precursor protein, or specific receptor, and reviewers have questioned whether the observed activity reflects a single, discrete endogenous molecule S1S2. The peptide is also reported to be short-lived, with rapid enzymatic breakdown described in laboratory settings S1.

Marketed as

On the research and gray market, DSIP is commonly promoted for sleep quality, relaxation, stress resilience, and recovery — the same themes that motivated the original studies S1. These are marketing claims and research hypotheses, not established clinical effects; the sections below describe what the evidence actually shows.

Regulatory status (US)

No DSIP product is approved by the FDA for any use, and DSIP has not completed the clinical-trial process required for drug approval S1. Material offered under the DSIP name is generally sold as a research chemical ("research use only") rather than as a medicine intended for human use S1. The broader 2026 landscape for peptide compounding is in flux (see What's changing).

Around the world

DSIP has never become a widely approved medicine. A DSIP preparation known as "Deltaran" has been described in some countries in preliminary clinical contexts, but the associated evidence is characterized as limited and early-stage S1. Across most jurisdictions there is no marketing authorization for a DSIP drug product S1.

Evidence

The scientific record on DSIP is old, small, and inconsistent. A comprehensive review catalogued a broad range of reported biological activities — spanning sleep, stress and temperature regulation, and hormone release — while noting how difficult these were to pin down S3. A later peer-reviewed review went further, describing the link between DSIP and sleep as "extremely poorly documented and still weak," and noting that artificial structural analogues, rather than the native peptide, produced the clearer sleep-related effects in animals S2. In humans, controlled work in chronic insomnia produced limited and mixed results rather than a robust, reproducible sleep benefit S4. More recent activity is preclinical: a 2024 study tested DSIP-based fusion peptides in a chemically induced insomnia mouse model S6. Taken together, the data remain unsettled and far from clinical proof.

Anti-doping

DSIP is not listed by name on the WADA Prohibited List S5. However, WADA's list includes a catch-all category (S0, "Non-Approved Substances") covering any substance with no current governmental approval for human therapeutic use that is not otherwise addressed on the list S5. Because DSIP has no such approval, athletes and support personnel should treat its status as prohibited-by-default under that provision and confirm current rules with their governing body S1S5.

Safety

Because DSIP has not been characterized in modern, adequately powered safety trials, its human safety profile is not well established S2. Products sold on the research/gray market are not quality-verified for human use, which adds uncertainty about identity, purity, and contamination S1. Anyone considering questions about DSIP should raise them with a qualified, licensed clinician rather than relying on vendor claims.

What's changing

The regulatory environment for research peptides is actively shifting in 2026, with ongoing discussion about which peptides may become eligible for pharmacy compounding under a physician-prescription model — a change that would not constitute FDA drug approval S6. At the same time, the modern scientific signal on DSIP remains preclinical, with new laboratory work exploring delivery and analogues rather than confirming clinical benefit S6. Whether any of this translates into validated human use remains an open question (see verify and open questions).